Drug intelligence / Profile preview

EK-001

Development stage: Unknown
Lead developer: Shanghai Enkai Cell Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

EK-001 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD19 antigen, currently under development by Shanghai Enkai Cell Technology (a subsidiary or associated entity of Shanghai NK Cell Technology). The therapy is designed to treat B-cell malignancies by genetically engineering a patient's T cells to express a receptor specific for CD19, a protein widely expressed on the surface of B-lineage cells. This modification enables the immune system to selectively recognize and eliminate cancerous B cells. EK-001 is currently being evaluated in Phase 1 clinical trials for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL).

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on EK-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EK-001.

Explore the full profile